TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Aditya Bardia; Komal Jhaveri; Kevin Kalinsky; Sonia Pernas; Junji Tsurutani; Binghe Xu; Erika Hamilton; Seock Ah Im; Zbigniew Nowecki; Joohyuk Sohn; Michelino De Laurentiis; Noelia Martínez Jañez; Barbara Adamo; Keun Seok Lee; Kyung Hae Jung; Gábor Rubovszky; Ling Ming Tseng; Yen Shen Lu; Yuan Yuan; Micah J. Maxwell; Vincent Haddad; Sabrina S. Khan; Hope S. Rugo; Barbara Pistilli

doi:10.2217/fon-2023-0188

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Aditya Bardia
, Komal Jhaveri
, Kevin Kalinsky
, Sonia Pernas
, Junji Tsurutani
, Binghe Xu
, Erika Hamilton
, Seock Ah Im
, Zbigniew Nowecki
, Joohyuk Sohn
, Michelino De Laurentiis
, Noelia Martínez Jañez
, Barbara Adamo
, Keun Seok Lee
, Kyung Hae Jung
, Gábor Rubovszky
, Ling Ming Tseng
, Yen Shen Lu
, Yuan Yuan
, Micah J. Maxwell

Vincent Haddad, Sabrina S. Khan, Hope S. Rugo, Barbara Pistilli

医学部

Massachusetts General Cancer Center
Memorial Sloan-Kettering Cancer Center
Cornell University
Emory University
Bellvitge Biomedical Research Institute
Showa Medical University
Sarah Cannon Research Institute
Seoul National University
Maria Sklodowska-Curie Institute of Oncology
Yonsei University
IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
Hospital Ramon y Cajal
University of Barcelona
National Cancer Center Korea
University of Ulsan
National Institute of Oncology
Veterans General Hospital-Taipei
National Taiwan University
City of Hope National Med Center
Cedars-Sinai Medical Center
AstraZeneca
University of California at San Francisco
Institut Gustave Roussy

科研成果: 期刊稿件 › 文献综述 › 同行评审

59 引用（Scopus）

摘要

Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).

源语言	英语
页（从-至）	423-436
页数	14
期刊	Future Oncology
卷	20
期	8
DOI	https://doi.org/10.2217/fon-2023-0188
出版状态	已出版 - 2023

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

可持续发展目标 3 良好健康与福祉

访问文件

10.2217/fon-2023-0188

其它文件与链接

链接到 Scopus 的出版物

引用此

Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S. A., Nowecki, Z., Sohn, J., De Laurentiis, M., Jañez, N. M., Adamo, B., Lee, K. S., Jung, K. H., Rubovszky, G., Tseng, L. M., Lu, Y. S., Yuan, Y., ... Pistilli, B. (2023). TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Future Oncology, 20(8), 423-436. https://doi.org/10.2217/fon-2023-0188

@article{752b73732cac417bb9e6b75383a60d26,

title = "TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer",

abstract = "Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).",

keywords = "ADC, antibody-drug conjugate, Dato-DXd, datopotamab deruxtecan, HR-positive/HER2-negative, inoperable breast cancer, metastatic breast cancer, TROP2, Trophoblast cell surface antigen 2",

author = "Aditya Bardia and Komal Jhaveri and Kevin Kalinsky and Sonia Pernas and Junji Tsurutani and Binghe Xu and Erika Hamilton and Im, \{Seock Ah\} and Zbigniew Nowecki and Joohyuk Sohn and \{De Laurentiis\}, Michelino and Ja{\~n}ez, \{Noelia Mart{\'i}nez\} and Barbara Adamo and Lee, \{Keun Seok\} and Jung, \{Kyung Hae\} and G{\'a}bor Rubovszky and Tseng, \{Ling Ming\} and Lu, \{Yen Shen\} and Yuan Yuan and Maxwell, \{Micah J.\} and Vincent Haddad and Khan, \{Sabrina S.\} and Rugo, \{Hope S.\} and Barbara Pistilli",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors.",

year = "2023",

doi = "10.2217/fon-2023-0188",

language = "英语",

volume = "20",

pages = "423--436",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

Bardia, A, Jhaveri, K, Kalinsky, K, Pernas, S, Tsurutani, J, Xu, B, Hamilton, E, Im, SA, Nowecki, Z, Sohn, J, De Laurentiis, M, Jañez, NM, Adamo, B, Lee, KS, Jung, KH, Rubovszky, G, Tseng, LM, Lu, YS, Yuan, Y, Maxwell, MJ, Haddad, V, Khan, SS, Rugo, HS & Pistilli, B 2023, 'TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer', Future Oncology, 卷 20, 号码 8, 页码 423-436. https://doi.org/10.2217/fon-2023-0188

TY - JOUR

T1 - TROPION-Breast01

T2 - Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

AU - Bardia, Aditya

AU - Jhaveri, Komal

AU - Kalinsky, Kevin

AU - Pernas, Sonia

AU - Tsurutani, Junji

AU - Xu, Binghe

AU - Hamilton, Erika

AU - Im, Seock Ah

AU - Nowecki, Zbigniew

AU - Sohn, Joohyuk

AU - De Laurentiis, Michelino

AU - Jañez, Noelia Martínez

AU - Adamo, Barbara

AU - Lee, Keun Seok

AU - Jung, Kyung Hae

AU - Rubovszky, Gábor

AU - Tseng, Ling Ming

AU - Lu, Yen Shen

AU - Yuan, Yuan

AU - Maxwell, Micah J.

AU - Haddad, Vincent

AU - Khan, Sabrina S.

AU - Rugo, Hope S.

AU - Pistilli, Barbara

PY - 2023

Y1 - 2023

N2 - Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).

AB - Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase III study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration:NCT05104866 (ClinicalTrials.gov).

KW - ADC

KW - antibody-drug conjugate

KW - Dato-DXd

KW - datopotamab deruxtecan

KW - HR-positive/HER2-negative

KW - inoperable breast cancer

KW - metastatic breast cancer

KW - TROP2

KW - Trophoblast cell surface antigen 2

UR - https://www.scopus.com/pages/publications/85188200861

U2 - 10.2217/fon-2023-0188

DO - 10.2217/fon-2023-0188

M3 - 文献综述

C2 - 37387213

AN - SCOPUS:85188200861

SN - 1479-6694

VL - 20

SP - 423

EP - 436

JO - Future Oncology

JF - Future Oncology

IS - 8

ER -

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

摘要

联合国可持续发展目标

访问文件

其它文件与链接

学术指纹

引用此